Navigation Links
Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss
Date:8/11/2009

itical, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of Aug. 11, 2009, and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove t
'/>"/>

SOURCE Amgen Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
2. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
3. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
4. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
5. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
8. Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies
9. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
10. Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms
11. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... March 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ... a focus on Omega-3 therapies for cardiovascular disease and ... issued 763,752 common shares of the Corporation (the "Common ... the period of December 5 th , 2014 to ... Notes that is due on or before April 1, ...
(Date:3/26/2015)... and VANCOUVER, British Columbia, March 26, 2015 /PRNewswire/ ... provided a summary of clinical developments and announced ... Clinical Developments and Anticipated Near-term ... OncoGenex and Teva agreed to negotiate the termination ... OncoGenex. Negotiations of the final termination agreement are ...
(Date:3/26/2015)... S.C. , March 26, 2015 ... told by their existing PACS vendor their system ... (CMH) determined that they needed a better structured ... Hospital selected Avreo interWORKS due to its interface ... modern meaningful use standards through to the hospital,s ...
Breaking Medicine Technology:Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8Clinch Memorial Hospital Modernizes Workflow with Avreo interWORKS 2
(Date:3/27/2015)... 2015 Airy Jeanine is a rising ... music video for her debut song “Mama’s Girl”, launched ... and abstract styling effects, the thematic video for the ... Vimeo, and assorted outlets. It will be integral in ... expanding full-scale marketing strategy. The video promotion campaign spearheaded ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 “ VXi ... of its monthly Tech Report, which features the latest ... a technology expert and special reporter for NewsWatch, conducted ... an advanced noise-cancelling headset, eliminating 90% of ambient noise. ... while texts and emails are important to any professional, ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 The ... a Quaker-based, philanthropic, grant-making foundation committed to raising ... behavioral healthcare is delivered. , The Scattergood Foundation ... advance Behavioral Health Policy and Practice through the ... SoundsLikeIBS Program App is designed to guide ...
(Date:3/26/2015)... Dallas, TX (PRWEB) March 26, 2015 ... of the 32nd annual Dallas Rhinoplasty Symposium and ... the years, reiterated the importance of evidence based medicine ... utilizing evidence from well conducted research. , "We often ... approaches to rhinoplasty, and while we are certainly not ...
(Date:3/26/2015)... San Francisco, CA (PRWEB) March 26, 2015 ... webinars. These will be on the topics of the DAOM ... , The DAOM Program Overview Webinar will be hosted by ... program and provide the next steps on how to prepare ... to 12:30 p.m. March 25, March 27, April 1 and ...
Breaking Medicine News(10 mins):Health News:Airy Jeanine Releases ‘’Mama’s Girl” Official Music Video 2Health News:A Device to Tune out Background Noise was Recently Featured on NewsWatch Television 2Health News:SoundsLikeIBS Nominated For 3rd Annual Scattergood Innovation Award 2Health News:Dr. Rod Rohrich Explores Evidence Based Innovations and Safety at the 32nd Annual Dallas Rhinoplasty Symposium 2Health News:ACTCM Announces Upcoming Webinars 2
... Recall covers last two years; lawmakers demand criminal probe ... peanut butter products in 2007 and 2008. , , WEDNESDAY, ... a startling nationwide recall late Wednesday for all peanut ... Georgia plant involved in the current salmonella outbreak. , ...
... be an effective way to reduce urinary incontinence in ... study led by researchers at the University of California, ... Reduce Incontinence by Diet and Exercise (PRIDE) experienced both ... frequency of their incontinence episodes, according to the study. ...
... MENLO PARK, Calif., Jan. 28 The Foundry, ... that it has completed a $5M,Series A financing ... Ventures,and Split Rock Partners, and added two new ... Both of the new partners have extensive experience ...
... control exercises, when performed in conjunction with other forms ... patients with persistent low back pain, according to a ... Physical Therapy ( PTJ ), the scientific ... addition to feeling less pain, patients performing these types ...
... N.J., Jan. 28 CCA Industries, ... announced today that the Board of ... dividend for the 1st Quarter ending ... Shareholders of record February 3, 2009 ...
... (NYSE: PRA ) announced today that ... with its proposed sponsored demutualization of,the PICA Group ... doctors of podiatric medicine. The proposed demutualization is ... a special meeting to be,held on March 31, ...
Cached Medicine News:Health News:All Products at Georgia Peanut Plant Recalled 2Health News:All Products at Georgia Peanut Plant Recalled 3Health News:All Products at Georgia Peanut Plant Recalled 4Health News:Weight loss reduces incontinence in obese women, UCSF study shows 2Health News:The Foundry Announces New Partners and Completion of Series A Financing for Eleventh Company 2Health News:The Foundry Announces New Partners and Completion of Series A Financing for Eleventh Company 3Health News:The Foundry Announces New Partners and Completion of Series A Financing for Eleventh Company 4Health News:Report shows motor control exercises reduce persistent low-back pain 2Health News:ProAssurance Receives Regulatory Approvals for Transactions with the PICA Group and Georgia Lawyers Insurance Company 2
Plastic Citrate Tube, .109M / 3.2%...
... Cross-match tubes are available ... serum tube contains a clotting ... cross-match tests where serum is ... EDTA cross-match tube is suitable ...
Inquire...
... EDTA K2 / gel tubes are ... for molecular diagnostics and for viral ... whole blood remain stable at room ... For optimal results, it is recommended ...
Medicine Products: